AUVI-Q (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. Approved for anaphylaxis. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AUVI-Q is an auto-injector formulation of epinephrine, an alpha-adrenergic agonist approved in 2012 for emergency treatment of anaphylaxis and other acute conditions including septic shock, cardiac arrest, and bronchospasm. The drug works by stimulating adrenergic receptors to restore cardiovascular function and reverse allergic/anaphylactic reactions. It is administered via intramuscular or subcutaneous injection as a pre-filled solution.
AUVI-Q is in peak commercial phase with stable Medicare Part D claims, suggesting mature market presence but limited growth runway and potential for right-sized team structures.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Worked on AUVI-Q at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAUVI-Q currently shows zero linked job postings, indicating minimal active recruitment for dedicated product roles; career opportunities likely embedded within broader Fresenius Kabi emergency care or specialty pharmacy teams. Roles typically available are maintenance-focused (brand management, medical education, patient support) rather than growth-oriented (launch, market expansion).